In the April issue of the “Hot Topics in Tech” newsletter series, we cover Generative Adversarial Networks (GAN) - a technique that promises to give imagination to artificial Intelligence (AI). This issue also briefly explores cultured meat and explores the potential impact of the recent FDA rulings on market and intellectual property activity.
FDA’s Center for Devices and Radiological Health (CDRH) approved a record-breaking 106 new medical devices in 2018. Medical devices approved by the FDA include Class I, Class II and Class III devices, categorized based on the potential risks involved in their use. Read all about it in this month's newsletter.
The pharma industry and US FDA will reflect on a record breaking 2018 for drug approvals. The Center for Drug Evaluation and Research (CDER) approved 59 new drugs last year which is a significant increase from previous years (FIG. 1; area plots). In the last 10 years, the FDA has approved 271 novel drugs and 85 biologics (FIG. 1, line plots). The new approvals for 2018 includes 42 new molecular entities and 17 new biologics. Small molecules dominate the list contributing to 64% of the approved drugs, while antibodies represent another 20%. There was a 40% increase in approvals of cancer therapies as compared to 2017. Increased approval trends were observed towards the end of the year with the last quarters accounting for more than 70% of the approved drugs. Oral dosage forms, such as tablets and capsules, accounted for greater than 80% of approved drugs (FIG. 2).
We have published the second volume of our newsletter which gives an insight into the patent publication trends of the past year. The classification has been done based on countries, companies, and more. The graphical representation of the various statistical values aim to provide an overview of how the patenting scenario has changed and the technologies which show promise for patents.
In the December issue of the “Hot Topics in Tech” newsletter series, we take a glance at how mobile devices have transformed healthcare and became a crucial component in the medical field.
In this issue of the "Hot Topics in Tech" series, we provide a brief overview of the patent filing activity around implantable non-energy based devices for hypertension treatment and management. We have also presented the top technologies within this domain, leading assignees, and market information.
This article provides a brief overview of the role of the autonomous nervous system in managing hypertension and describes various techniques related to neurostimulation. Patents revealing various energy-based techniques for neurostimulation, and devices related thereto which are available in the market are also presented.
This issue covers cardiovascular diseases and discloses the technological categories and products related to the use of renal denervation approach for managing hypertension. It also talks about the three main categories of Artificial Intelligence namely Artificial Narrow Intelligence (ANI), Artificial General Intelligence (AGI), and Artificial Super Intelligence (ASI). They influence human life in the form of automated cars, virtual assistants, image recognition software, robotics, games, life science and so on. Read more on this report.
In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some
insights about the company alongwith a quick run-through of the firm's recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification.
In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA's approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018.